[go: up one dir, main page]

Verheijden et al., 1997 - Google Patents

Human cartilage glycoprotein‐39 as a candidate autoantigen in rheumatoid arthritis

Verheijden et al., 1997

Document ID
790639495662594365
Author
Verheijden G
Rijnders A
Bos E
Coenen‐De Roo C
van Staveren C
Miltenburg A
Meijerink J
Elewaut D
De Keyser F
Veys E
Boots A
Publication year
Publication venue
Arthritis & Rheumatism: Official Journal of the American College of Rheumatology

External Links

Snippet

Objective. To identify a cartilage‐derived autoantigen that is relevant to the rheumatoid arthritis (RA) disease process. Methods. A DR4 (DRB1* 0401) peptide binding motif was used for the selection of potential self reactive peptides within human cartilage glycoprotein …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/564—Immunoassay; Biospecific binding assay for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Verheijden et al. Human cartilage glycoprotein‐39 as a candidate autoantigen in rheumatoid arthritis
Stepaniak et al. A comparative study of experimental autoimmune encephalomyelitis in Lewis and DA rats.
Taneja et al. HLA class II transgenic mice as models of human diseases
Cope et al. T cell responses to a human cartilage autoantigen in the context of rheumatoid arthritis–associated and nonassociated HLA–DR4 alleles
US8053235B2 (en) Methods of generating antigen-specific CD4+CD25+regulatory T cells, compositions and methods of use
Hawkes et al. T-cell lines reactive to an immunodominant epitope of the tyrosine phosphatase-like autoantigen IA-2 in type 1 diabetes.
US5736507A (en) Peptides derived from autoantigen for use in immunotherapy of autoimmue diseases
US20250332229A1 (en) Immunodominant proteins and fragments in multiple sclerosis
US20100324829A1 (en) Method of selecting hla-dp4 ligands and the applications thereof
Honma et al. Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8+ cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism
JP3434510B2 (en) Inhibition of T-cell proliferation using peptide fragments of myelin basic protein
Hirose et al. Lymphocyte responses to retinal-specific antigens in uveitis patients and healthy subjects
Monneaux et al. B and T cell immune response to small nuclear ribonucleoprotein particles in lupus mice: autoreactive CD4+ T cells recognize a T cell epitope located within the RNP80 motif of the 70K protein
Chou et al. Specificity of human T cell clones reactive to immunodominant epitopes of myelin basic protein
US20230340061A1 (en) Peptides and methods for the treatment of multiple sclerosis
van Noort et al. Minor myelin proteins can be majot targets for peripheral blood T cells from both multiple sclerosis patients and healthy subjects
EP2156183B1 (en) Prognostic assay for determining t cell response to hla antigens and use thereof in field of tissue transplantation
US20080193457A1 (en) Ra Antigenic Peptides
Kammerer et al. Delineation of PLA2 epitopes using short or long overlapping synthetic peptides: interest for specific immunotherapy
Roudier et al. Tolerance to a self peptide from the third hypervariable region of the E chain. Implications for molecular mimicry models of autoimmune disease
Boots et al. Selection of self-reactive peptides within human aggrecan by use of a HLA-DRB1* 0401 peptide binding motif
JP2010235607A (en) Peptides as diagnostic and therapeutic agent for autoimmune diseases
Massacesi et al. Induction of experimental autoimmune encephalomyelitis in rats and immune response to myelin basic protein in lipid-bound form
Immonen et al. Use of multiple peptides containing T cell epitopes is a feasible approach for peptide‐based immunotherapy in Can f 1 allergy
Juntunen et al. Suboptimal recognition of a T cell epitope of the major dog allergen Can f 1 by human T cells